Kit S. Lam


	Kit S. Lam

UC Davis Cancer Center

Professor/Chief, UCD, Med, Int Med, Hematology Oncology

kit.lam@ucdmc.ucdavis.edu

Univ of Wisconsin, Oncology, PhD, 1975 - 1980

Stanford Univ, Medicine, MD, 1980 - 1984

UC Davis, Hem/Onc, Chief, 1999

Molecular Biology Research Dr. Lam has expertise in lymphoma, peptide-body and peptide-receptor interaction. His clinical interests also include monoclonal antibodies, leukemia, drug development, and combinatorial chemistry. His research interests include peptide and small molecule combinatorial chemistry, protein tyrosine kinases, peptide-targeted cancer therapy, and proteomics.

Research Areas Breast Cancer, Cancer & Carcinogenesis, Pharmacology, Biology, Cellular

Selected Publications

Liu R, Hsieh CY, Lam KS. New approaches in identifying drugs to inactivate oncogene products. Semin Cancer Biol. 14: (1) 13-21. (2004)

Hwang SH, Lehman A, Cong X, Olmstead MM, Lam KS, Lebrilla CB, Kurth MJ. OBOC small-molecule combinatorial library encoded by halogenated mass-tags. Org Lett. 6: (21) 3829-32. (2004)

Song A, Wang X, Zhang J, Marik J, Lebrilla CB, and Lam KS. Synthesis of hydrophilic and flexible linkers for peptide derivatization in solid phase. Bioorg Med Chem Lett. 14: (1) 161-165. (2004)

Wang X, Zhang J, Song A, Lebrilla CB, and Lam KS. Encoding method for OBOC small molecule libraries using a biphasic approach for ladder-synthesis of coding tags. Am Chem Soc. 126: (18) 5740-5749. (2004)

Katsushi A, Leung PSC, Xu Q, Marik J, Quan C, Kurth MJ, Nantz MH, Ansari AA, Lam KS, Zeniya M, Coppel RL, Gershwin ME. Xenobiotic-induced loss of tolerance in rabbits to the mitochondrial autoantigen of primary biliary cirrhosis is reversible. J Immunol. 172: (10) 6444-6452. (2004)

Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'donnell RT, Richman C, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara DR, Lara PN Jr. An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. Cancer J. 10: (5) 294-300. (2004)